Author(s):
1. Bojan Pavičar, Affidea, Internacionalni medicinski centar, Centar za Radioterapiju, Dvanaest beba bb, Banja Luka, Pr, Republic of Srpska, Bosnia and Herzegovina
2. Andrej Milosavljević, Center for Radiation Therapy, International Medical Centers, Affidea, Banja Luka, Bosnia and Herzego, Republic of Srpska, Bosnia and Herzegovina
3. Milomir Milaković, Center for Radiation Therapy, International Medical Centers, Affidea, Banja Luka, Bosnia and Herzego, Republic of Srpska, Bosnia and Herzegovina
4. Tatjana Ignjić, IMC Banja Luka - Affidea, Republic of Srpska, Bosnia and Herzegovina
5. Petar Janjic, IMC Banja Luka, Republic of Srpska, Bosnia and Herzegovina
6. Mihajlo Tovilović, Center for Radiation Therapy, International Medical Centers, Affidea, Banja Luka, Bosnia and Herzego, Republic of Srpska, Bosnia and Herzegovina
7. Goran Kolarević, Republic of Srpska, Bosnia and Herzegovina
8. Dragoljub Mirjanić, Akademija nauka i umjetnosti Republike Srpske, Republic of Srpska, Bosnia and Herzegovina

Abstract:
This study compares the dosimetric effects of the American Association of Physicists in Medicine (AAPM) TG-43 dose formalism and the Acuros BV (grid-based Boltzmann solver, GBBS) formalism on high-dose-rate (HDR) brachytherapy planning for cervical cancer patients treated with a tandem and ring applicator. Ten cervical cancer patients were included in the study. The high-risk clinical target volume (HR-CTV) and organs at risk (OARs) were delineated using computed tomography (CT) imaging and manual contouring methods. The doses to HR-CTV were assessed using D50%, D90%, and D98% metrics, while for OARs, D2cc doses were compared. For HR-CTV, the dose differences between TG-43 and Acuros BV were as follows: D50% (1.9%), D90% (2.6%), and D98% (3.4%). For OARs, the D2cc dose differences were: bladder (3.0%), rectum (2.6%), small bowel (2.8%), and sigmoid colon (2.9%). Overall, the study demonstrates that while both TG-43 and Acuros BV formalisms provide comparable dosimetric outcomes for HDR brachytherapy of cervical cancer, Acuros BV offers slight dose reductions across HR-CTV and OARs. The differences in dosimetric parameters between TG-43 and Acuros BV are statistically significant (p=0.05), but their clinical significance has yet to be examined.

Key words:
HDR Brachytherapy,Cervical Cancer,TG-43 Algorithm,Acuros BV,Dosimetry

Thematic field:
SYMPOSIUM B - Biomaterials and nanomedicine

Date of abstract submission:
15.07.2024.

Conference:
Contemporary Materials 2024 - Savremeni Materijali

Abstract